Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study

Autor: Xing Gao, Zhi-Hao Yang, Yi-Hsuan Cheng, Chun-Ling Chi, Tzu-Yi Yang, Kai-Hao Chuang, Chiao-En Wu, Joseph Jan-Baptist van Lanschot, Yu-Wen Wen, Yin-Kai Chao

Publikováno v: Diseases of the Esophagus.

Summary High-quality evidence indicated that both neoadjuvant carboplatin/paclitaxel (CROSS) and cisplatin/5-fluorouracil (PF) regimens in combination with radiotherapy improve survival outcomes compared to surgery alone in patients with esophageal c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1111611967dca388981c56716cc1c751
https://doi.org/10.1093/dote/doad031

377. NEOADJUVANT CARBOPLATIN/PACLITAXEL VERSUS 5-FLUOROURACIL/CISPLATIN IN COMBINATION WITH RADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A MULTICENTER COMPARATIVE STUDY

Autor: Xing Gao, PingChung Tsai, KaiHao Chuang, ChuPin Pai, PoKuei Hsu, ShauHsuan Lee, HungI Lu, Joseph Jan-Baptist van Lanschot, YinKai Chao

Publikováno v: Diseases of the Esophagus. 35

Treatment options for esophageal cancer (EC) have rapidly expanded from surgery alone to multimodal approaches comprising surgery, chemotherapy or radiotherapy. High-quality evidence from clinical trials indicated that both carboplatin/paclitaxel (CR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25b83fead8555eb871b09275690c38d0
https://doi.org/10.1093/dote/doac051.377

Neoadjuvant Carboplatin/Paclitaxel versus 5-Fluorouracil/Cisplatin in Combination with Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Comparative Study

Autor: Xing Gao, Ping-Chung Tsai, Kai-Hao Chuang, Chu-Pin Pai, Po-Kuei Hsu, Shau-Hsuan Li, Hung-I Lu, Joseph Jan-Baptist van Lanschot, Yin-Kai Chao

Publikováno v: Cancers, 14(11):2610. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers; Volume 14; Issue 11; Pages: 2610

Background: The most beneficial neoadjuvant chemoradiotherapy (nCRT) combination for esophageal squamous cell carcinoma (ESCC) in Asia remains uncertain. Herein, we compared the neoadjuvant carboplatin/paclitaxel (CROSS) regimen versus the cisplatin/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ef5883a244418faef65d1e80b57cdf5
https://pubmed.ncbi.nlm.nih.gov/35681592